The Prescribing Information is the primary source of information on the known and potential risks of ocrelizumab for relapsing forms of multiple sclerosis (RMS) or primary progressive multiple sclerosis (PPMS).

As of December 2020, more than 200,000 patients with RMS and PPMS have started ocrelizumab globally, amounting to a total of more than 300,000 patient-years.1

The following ocrelizumab global safety updates are available. Click below to learn more:

Updated Safety Analysis

Additional Topics of Interest

Post-marketing Commitments


Ocrelizumab is indicated for the treatment of: 

  • Relapsing forms of multiple sclerosis (MS), to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in adults
  • Primary progressive MS, in adults


Report an Adverse Event:
Phone: (888) 835-2555
Hours: 24 hrs/day, 7 days/week

Medical Communications:
Submit a question online
Phone: (800) 821-8590
Hours: Monday - Friday, 5am - 5pm PT

Contact an MSL:
Request follow-up with a Genentech medical science liaison (MSL)


Genentech data on file: December 31, 2020, post-marketing experience; March 27, 2020, clinical trials data cut-off